


NIDA Update: *Overdose, Vaping, Cannabis, Stimulants*



Wilson M. Compton, M.D., M.P.E.


Deputy Director

National Institute on Drug Abuse



Increased Drug *Overdose* Death Rates

Estimated Age-adjusted Death Rates per 100,000 for Drug Poisoning by County.

2003




2017



SOURCE: National Center for Health Statistics, National Vital Statistics System, mortality data (<http://www.cdc.gov/nchs/deaths.htm>).

Evolution of Drivers of Overdose Deaths:


Analgesics ➡ *Heroin* ➡ *“Fentanyl”* ➡ *Stimulants*



See: Compton WM & Jones CM, Ann NY Acad Sci, 2019;
Updated for 2019 from WONDER Database

Recent Changes in Overdose Deaths

Figure 1a. 12 Month-ending Provisional Counts of Drug Overdose Deaths: United States



NCHS Provisional Drug Overdose Death Counts: <https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm>
(downloaded 1-18-2021)


Overdose Deaths Continued to Increase in 2020

	ALL DRUGS	HEROIN	NAT & SEMI – SYNTHETIC	METHADONE	SYNTHETIC OPIOIDS	COCAINE	OTHER PSYCHO- STIMULANTS (mainly meth)
January 2020 *	72,731	14,175	12,107	2,795	37,054	16,522	16,882
March 2020*	75,687	14,145	12,349	2,837	40,756	17,465	18,033
June 2020*	83,335	14,480	12,966	3,195	48,006	19,215	20,318
Jan 2020-June 2020 Change	14.6%	2.2%	7.1%	14.3%	29.6%	16.3%	20.4%

NCHS Provisional Drug Overdose Death Counts: <https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm> (as of January 18, 2021)

ENVIRONMENTAL AVAILABILITY: Current Opioid Crisis Originated with Prescribing Increases


Opioid prescriptions
*Tripled to MORE THAN
200 MILLION prescriptions
in the 2000's*



From Prescriptions to Misuse: *Direct Pathways*

- *People misusing analgesics **Directly** obtain them by their own prescriptions*


Source where pain relievers obtained for most recent misuse



From Prescriptions to Misuse: *Direct Pathways* and *Indirect*

- *People misusing analgesics **Directly** obtain them by their own prescriptions, as well as **Indirectly** from prescriptions of friends and relatives*

Source where pain relievers obtained for most recent misuse



Source: Han, Compton, et al. Annals of Internal Medicine 2017

ECONOMICS: Heroin Increases Due to Lower Price and Greater Availability


The relentless marketing of pain pills. Crews from one small Mexican town selling heroin like pizza. The collision has led to America's greatest drug scourge.

The True Tale of America's Opiate Epidemic

DREAM LAND

SAM QUINONES

"Retail" Price Per Pure Gram



National Drug Control Strategy--Data Supplement 2014.

https://www.whitehouse.gov/sites/default/files/ondcp/policy-and-research/ndcs_data_supplement_2014.pdf


ECONOMICS:

CHEAP Fentanyl Precursor Chemicals

Criminal Chemistry

Traffickers manufacturing fentanyl often purchase the key ingredient from China, which doesn't regulate its sale. Here's how the chemical building blocks become a highly profitable street drug.

The key ingredient is **NPP**,
25 grams of which can be
bought from China for
about **\$87***



NPP can be combined with
about **\$720** of **other
chemicals†** to produce
fentanyl.

**The resulting 25 grams of
fentanyl cost about \$810 to
produce...**

**...and are equivalent to up to
\$800,000 of pills on the black
market.**

*Average current price from Chinese suppliers

†Prices from U.S. suppliers


Sources: NES Inc.; Drug Enforcement Administration;
Calgary Police

THE WALL STREET JOURNAL.

Additional Consequences of Addiction


- Drug use while pregnant or parenting has led to increases in rates of neonatal abstinence syndrome and removal of children into the foster care system.
- Increased rates of injection drug use have led to increases in acute cases of Hepatitis C and outbreaks of HIV

U.S. Foster Care Removals for Infants < 1 Y.O.



Source: Patrick SW, Frank RG, et al. *Hospital Pediatrics*, 2019.


Acute Cases of HCV in USA



Zibbell et al. *Am J Public Health* 2018;108:175-181


Overlap of *Benzodiazepines and Opioids*

Opioid Analgesic ED Visits and OD Deaths Involving Benzodiazepines & Benzodiazepine ED Visits and OD Deaths Involving Opioids



Doctors Continue to Prescribe Opioids for *Ninety-one Percent* of Overdose Patients

In a *2-year follow-up of 2848 commercially insured patients who had a nonfatal opioid overdose* during long-term opioid therapy :




➤ *33-39% of those with active opioid prescriptions during follow-up also were prescribed benzodiazepines.*

Question:

What can you do to address these issues?

Medical Examiner Letter Reduces Subsequent Prescribing: Randomized trial of 861 clinicians prescribing to 170 OD decedents

Intervention group received notification of their patients' deaths and a safe prescribing injunction from their county's medical examiner; control group did not. Milligram morphine equivalents in prescriptions filled by patients of letter recipients decreased by 9.7% (95% confidence interval: 6.2 to 13.2%; $P < 0.001$) over 3 months after intervention; also, fewer opioid initiates and fewer high-dose opioid prescriptions.



Source: Doctor, et al. *Science* 2018;361(6402):588-590.

Solutions toward *Responsible Prescribing*: Guidance



Opioid Prescribing Guidelines March 2016

- Intended for primary care providers
- Applies to patients >18 years old in chronic pain outside of end-of-life care
- ***Focuses on:***
 - Determining when to initiate or continue opioids for chronic pain
 - Opioid selection, dosage, duration, follow-up and discontinuation
 - Assessing risk and addressing harms of opioid use



Dowell, Compton, Giroir.
2019;322(19):1855–1856

Patient-Centered Reduction or Discontinuation of Long-term Opioid Analgesics:

The HHS Guide for Clinicians

Focuses on:

- (1) Criteria for reducing or discontinuing opioid therapy
- (2) Considerations prior to deciding to taper opioids
- (3) Ensuring patient safety prior to initiating taper
- (4) Shared decision-making with patients
- (5) Rate of opioid taper
- (6) Opioid withdrawal management
- (7) Behavioral health support
- (8) Challenges to tapering

Dosage changes, particularly rapid reductions in dose, can harm patients or put them at risk if not made in a thoughtful, deliberative, collaborative, and measured manner.

Naloxone Distribution

Direct intervention to save lives: *Nasal spray and Auto-injector* formulations



April 5, 2018

Surgeon General's Advisory on Naloxone and Opioid Overdose

I, Surgeon General of the United States Public Health Service, VADM Jerome Adams, am emphasizing the importance of the overdose-reversing drug naloxone. For patients currently taking high doses of opioids as prescribed for pain, individuals misusing prescription opioids, individuals using illicit opioids such as heroin or fentanyl, health care practitioners, family and friends of people who have an opioid use disorder, and community members who come into contact with people at risk for opioid overdose, knowing how to use naloxone and keeping it within reach can save a life.

BE PREPARED. GET NALOXONE. SAVE A LIFE.



Next steps

- *Longer acting agents to address fentanyl risks?*
- *Respiratory stimulation?*
- *Device development?*

The National Academies of
SCIENCES • ENGINEERING • MEDICINE

CONSENSUS STUDY REPORT

MEDICATIONS
FOR
OPIOID
USE
DISORDER
SAVE
LIVES


Medications for Opioid Use Disorder
are underutilized, and
Relapse rates are very high!

Science = Solutions: Improving Addiction Treatment


- Initiating buprenorphine treatment in the **emergency department** improves treatment engagement and reduces illicit opioid use
- Extended release naltrexone initiated in **criminal justice** settings lowers relapse rates and overdoses
- BUP-Nx** more effective than **XR-Naltrexone** overall but appear equally safe and effective after induction




Post Prison-Release Outcomes



Lee JD, et al., *Addiction* 2015;100:1005-1014
and *New Eng J Med* 2016;374:1232-1242



ED-initiated Buprenorphine Increased TX Engagement






<https://heal.nih.gov/>

Scientific solutions to the opioids crisis

- \$500M/year effort
 - > \$945M obligated in FY2019
 - 40+ funding opportunity announcements
 - 41 states
 - 400 Investigators
- > 25 HEAL research programs
 - 12 NIH Institute and Centers
 - From prevention, basic and translational research, clinical trials, to implementation science
- Research ongoing for years to come

HELPING END ADDICTION LONG TERMSM (HEAL) Initiative




<https://heal.nih.gov/>

Question:

***How does the SARS-Cov-2
pandemic intersect with the
overdose crisis?***

Overdoses Grew During SARS-CoV-2 Pandemic at a Faster Pace than Early 2020

Overdoses increased up to 42% per month during the pandemic, as compared to the same months in 2019.



Note: Percent growth references the 1,201 agencies reporting to ODMAP by January 1, 2020.


Source: ODMAP



ALYSSA FOWERS/THE WASHINGTON PO

Increased Overdose-Related Cardiac Arrests During the US COVID-19 Epidemic


A Overdose-related cardiac arrests



Overdose-related cardiac arrests per 100 000 EMS calls for 2018 through August 2020. (Average of 2018 and 2019 values is the dotted black line.)


Vertical dashed line marks March 16, when mobility first markedly decreased nationally in the US.

B Change in mobility and opioid-related incidents




Elevation in 2020 over baseline values in overdose-related cardiac arrests and all overdose-related EMS calls alongside changes in mobility

Drug Use Increases During Pandemic



Millennium Health Signals Report™ COVID-19
Special Edition: Significant Changes in Drug Use
During the Pandemic Volume 2.1 Published July
2020

Fentanyl Positivity, by Age and Sex, Before and During COVID-19




Niles JK et al., Population Health Management, 2020.

Increased Overdose Death Rates During COVID-19 Pandemic


12-months Ending June 2019 Compared to 12-months Ending May 2020

Primarily Driven by Synthetic Opioids




38.4% increase in synthetic opioid OD deaths across U.S.

- ↑ 98.0% - 10 western states
- ↑ 35.4% - 12 southern states & DC
- ↑ 32.1% - 6 midwestern states
- ↑ 21.1% - 8 northeastern states & NYC



MAT Prescribing During Early Pandemic, March 2020-May 2020


- Extended-release intramuscular naltrexone prescriptions fell statistically significantly *below forecasted levels*
 - Suggests patients had difficulty obtaining XR-BUP due to healthcare provider office closures and need for provider to administer medication
- Buprenorphine and naloxone prescribing was at forecasted levels
- Comparison prescriptions for other conditions were *above* forecasted levels in March; at forecasted levels April-May
 - Reflects public health recommendations to increase medication supplies on hand



COVID-19 in patients with substance use disorders

(based on U.S. Electronic Health Records)

Risk Associated with Recent SUD Diagnosis and COVID-19



Structural and Social Challenges for SUD During SARS-CoV-2

- *Stress and Stigma*
- *Limited medication access and limited peer-support groups/social connection*
- *Social distancing increases likelihood of opioid overdoses happening with no observers who can administer naloxone*
- *Job losses*
- *Housing instability/homelessness*
- *Incarceration (>50% of U.S prisoners have SUD) and prison populations are at greatest risk SARS-CoV-2 transmission*



*Buffalo NY Methadone Clinic
March 2020*



Service Shifts in SARS-CoV-2 Pandemic


- Increased use of telemedicine
- Establishment of mental health hot lines
- Deployment of virtual support meetings
- Expansion of take-home medicines for MOUD
- Buprenorphine prescribing via Telehealth
- Release of non-violent offenders with SUD from jails and prisons(might improve their outcomes)
- Development of web-based educational material that can be used to help in rehabilitation

Teen Nicotine Vaping Climbs Significantly *(and threatens progress in tobacco control)*

Daily Nicotine Vaping
Measured for the
first time in 2019



Past Month Nicotine Vaping




**Past month
nicotine vaping
Equates to:**

1 in 10–8th graders
1 in 5–10th graders
1 in 4–12th graders

2019 Monitoring the Future Survey

More U.S. Youth Use E-Cigs Than Combustible Cigs

2019 Past Month E-Cig vs. Combustibles in USA Students



5.3 million U.S. middle and high-school students reported vaping in 2019

Cullen et al. JAMA, November 5, 2019

E-Cigarette Use *May Lead to Combustible Cigs*

In a prospective study of 14 year old students,
E-Cigarette use predicted onset of—

- Any Combustible Tobacco Product: 2.75 times more likely (AOR-adjusted odds ratio)
- Smoking Cigarettes 1.73 more likely (AOR)

Leventhal, et al. *JAMA* 2015;314(7):700-707.

In a prospective study of 12-15 year olds,
E-Cigarette use predicting onset 2 years later of—

- Ever Using Cigarettes: 4.09 times more likely (AOR)
- Currently Smoking Cigarettes: 2.75 times more likely (AOR)

Berry, et al. *JAMA Network Open* 2019;2(2):e187794

Safer $\neq$ Safe

Generally Higher Levels of Toxic Compounds in Conventional Cigarettes than E-Cigarettes (*but not zero levels*)

Toxic Compound	Conventional Cigarette (ug)	E-cigarette (ug / 15 puffs)	Conventional vs E-cigarette
Formaldehyde	1.6-5.5	0.2-5.61	9
Acetaldehyde	52-140	0.11-1.36	130
Acrolein	4.6-14	0.07-4.19	4
Toluene	6.4-9.0	0.02-0.63	23
NNN	0.012-0.37	0.00008-0.00043	145
NNK	0.009-0.08	0.00011-0.00283	30
Cd	0.03-0.35	0.001-0.022	16
Ni	0.003-0.60	0.011-0.029	15


Question:

How can clinicians address youth vaping?


How do we balance potential benefits (to smokers who can't quit using other approaches) *vs. harms from vaping?*

Teen Marijuana Vaping Climbs Significantly

Daily Marijuana Vaping Measured for the first time in 2019



Past Month Marijuana Vaping



The 2018-2019 increase is the second largest 1-year jump ever tracked for any substance in the 45-year survey.

2019 Monitoring the Future Survey
Miech, et al. JAMA. Dec 17, 2019.

Variation in *Legal Status* of Cannabis



Marijuana

State

2020 Recreational
Marijuana


2018 Comprehensive
Medical Marijuana

2018 Recreational
Marijuana

2020 Recreational
Marijuana

2020 Recreational
Marijuana

2020 Comprehensive
Medical Marijuana



■ MEDICINAL & RECREATIONAL LAWS	■ LIMITED MEDICINAL MARIJUANA LAWS (LOW TETRAHYDROCANNABINOL (THC), HIGH CANNABIDIOL (CBD))
■ COMPREHENSIVE MEDICAL MARIJUANA LAWS	□ NO MARIJUANA ACCESS


REFERENCES
cannabismatters.com
cannabismatters.com
cannabismatters.com

STATES LAWS STATUS CURRENT AS OF DECEMBER 28,
LOCAL GOVERNMENT WEBSITES HAVE ADDITIONAL INFORMATION ON THE LAWS
REGARDING MEDICINAL AND RECREATIONAL MARIJUANA ON A STATE-BY-STATE BASIS.


MULTIPLE STUDIES SHOW ALTERED BRAIN STRUCTURE AND FUNCTION IN YOUTH WHO REGULARLY USE CANNABIS

Early (<18y) Cannabis Use Decreases Axonal Fiber Connectivity

Precuneus
to splenium



Fimbria of
hippocampus,
hippocampal
Commissure,
and
splenium



Axonal paths with reduced connectivity (measured with diffusion-weighted MRI) in cannabis users (n=59) than in controls (N=33).



PATH

Population Assessment
of Tobacco and Health

A collaboration between the NIH and FDA

- **More than 5 years of data collection, starting with 45,971 adults and youth participants (ages 12 and up)**
- **Data access at <http://www.icpsr.umich.edu/icpsrweb/NAHDAP/series/606>**



Adolescent Brain Cognitive Development

Teen Brains. Today's Science. Brighter Future.

An NIH Collaboration: NIDA, NIAAA, NCI, NIMH, NIMHD, NICHD, NINDS, OBSSR


- **Baseline data collection complete—11,878 children ages 9-10**
- **Longitudinal Data—*in process***
- **Easy and data access.**
- **See abcdstudy.org**

Question:


How can clinicians address cannabis use by youth?

What about for adult patients?


Psychostimulant Drugs




cocaine




d-methamphetamine




MDMA



methylphenidate




modafinil




amphetamine

METH: Addictive and Toxic, Serious Mental Illness, Difficult to Treat


- **Acute:** increased alertness/energy, aggression/violence, psychosis, suicidality/homicidality with binge use; vasoconstrictor: HTN, cardiovascular stimulant, seizures, fatal cardiac complications and strokes; common ED presentations: trauma
- **Chronic:** difficulty feeling any pleasure other than provided by the drug
- **Co-occurring mental disorders:** psychosis, violent behaviors, depression
- **Treatment:** No medications; treat with behavioral therapies in the context of drug cravings and cognitive deficits can lead to poor retention, poor outcomes, frequent relapse




Distribution of METH in Brain and Body




Brain Dopamine System




Anatomy




DA Transporters



DA Receptors





Dopamine Cell




Metabolism

Dopamine D2 Receptors are Lower in Addiction





Non-Drug User



Drug User




Dopamine Transporters in Methamphetamine Users




Methamphetamine users have significant reductions in dopamine transporters

Chronic Drug Use Disrupts Inhibitory Control

Correlations Between D2 Receptors in Striatum and Brain Glucose Metabolism






Partial *Recovery* of Brain Dopamine Transporters in Methamphetamine User After Protracted Abstinence



Source: Volkow, ND et al., *Journal of Neuroscience* 21, 9414-9418, 2001.

Social Interaction Preferred Over Methamphetamine

Drug preference increases when social reward is devalued by delay or punishment




Venniro et al., 2018

Universal Drug Abuse Prevention:

Studies suggest impact on opioids and methamphetamine

Past Year Methamphetamine Use 4½ to 6½ Years Past Baseline




***Targeting Youth to
Prevent Later Substance
Use Disorder: An
Underutilized Response to
the US Opioid Crisis***

Compton WM, Jones CM, Baldwin GT,
Harding FM, Blanco C, Wargo EM
American Journal of Public Health
2019;109:2185-S189.

Note: Study 2 included both ISFP and LST interventions

Source: R Spoth et al. *Arch Pediatr Adolesc Med* 2006;160:876-882

ER-Naltrexone (380 mg/month) plus ER Bupropion (450 mg/day) for Methamphetamine Use Disorder (n=403 [phase 1], 225 [phase 2])



Conclusions:

“Among adults with methamphetamine use disorder, the response over a period of 12 weeks among participants who received extended-release injectable naltrexone plus oral extended-release bupropion was low but was higher than that among participants who received placebo.”

Summary:

- Complex biological, developmental and social aspects of substance use and addiction suggest *multipronged responses*.
- The severity of **ADDICTION** demands *urgent action*.

NIDAMED 

*Resources for Medical Students,
Resident Physicians & Faculty*

www.drugabuse.gov/coe



www.drugabuse.gov

Science = Solutions